ReviewGenetics in medicine : official journal of the American College of Medical Genetics2013
Mapping the incidentalome: estimating incidental findings generated through clinical pharmacogenomics testing.
Review in Genetics in medicine : official journal of the American College of Medical Genetics, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed.
- Assessment of the current status of real-world pharmacogenomic testing: informed consent, patient education, and related practices.Frontiers in pharmacology · 2024Article
- A paradigm shift in pharmacogenomics: From candidate polymorphisms to comprehensive sequencing.Basic & clinical pharmacology & toxicology · 2022Review
- Revisiting Secondary Information Related to Pharmacogenetic Testing.Frontiers in genetics · 2021Article
- Applying Next-Generation Sequencing Platforms for Pharmacogenomic Testing in Clinical Practice.Frontiers in pharmacology · 2021Review
- Projected Prevalence of Actionable Pharmacogenetic Variants and Level A Drugs Prescribed Among US Veterans Health Administration Pharmacy Users.JAMA network open · 2019Observational
- A qualitative analysis of the attitudes of Irish patients towards participation in genetic-based research.Irish journal of medical science · 2016Article
- Evidence for extensive pleiotropy among pharmacogenes.Pharmacogenomics · 2016Article
- Public preferences for the return of research results in genetic research: a conjoint analysis.Genetics in medicine : official journal of the American College of Medical Genetics · 2014Article
- Secondary use of clinical data: the Vanderbilt approach.Journal of biomedical informatics · 2014Article
- Personalized sequencing and the future of medicine: discovery, diagnosis and defeat of disease.Pharmacogenomics · 2014Article
- Teaching genomic counseling: preparing the genetic counseling workforce for the genomic era.Journal of genetic counseling · 2014Article
- Comparison of delivery strategies for pharmacogenetic testing services.Pharmacogenetics and genomics · 2014Review
- A framework for analyzing the ethics of disclosing genetic research findings.The Journal of law, medicine & ethics : a journal of the American Society of Law, Medicine & Ethics · 2014Article
- SLCO1B1 Polymorphisms and Statin-Induced Myopathy.PLoS currents · 2013Article
- Ethical, legal, and social implications of incorporating genomic information into electronic health records.Genetics in medicine : official journal of the American College of Medical Genetics · 2013Review
- Implications of the incidentalome for clinical pharmacogenomics.Pharmacogenomics · 2013Article
- Ethical issues in pediatric pharmacogenomics.The journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG · 2013Article
- Implementation of a clinical research pharmacogenomics program at an academic medical center: role of the genetics healthcare professional.Pharmacogenomics · 2013Article
- Return of individual research results and incidental findings: facing the challenges of translational science.Annual review of genomics and human genetics · 2013Review
- Informed consent in the era of biobanks.Genome medicine · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
purposeGreater clinical validity and economic feasibility are driving the more widespread use of multiplex genetic technologies in routine clinical care, especially for applications in pharmacogenomics. Empirical data on the numbers and types of incidental findings generated through such testing are needed to develop policies and practices related to their clinical use. Of particular importance are disparities in findings relevant to different ancestry groups.
methodsThe Pharmacogenomic Resource for Enhanced Decisions in Care and Treatment Resource, or PREDICT, is an institutional program to implement prospective clinical genotyping of 34 pharmacogenomic-related genes to guide drug selection and dosing. We curated 5,566 journal articles to quantify and characterize the incidental, non-pharmacogenomic genotype-phenotype associations that could be generated through this clinical genotyping project.
resultsWe identified 372 putative incidental genotype-phenotype associations that might be revealed in patients undergoing clinical genotyping for pharmacogenomic purposes. Of these, 287 associations were supported by at least one study demonstrating an odds ratio ≥2.0 or ≤0.5. Numbers of potentially relevant findings varied widely by ancestry group.
conclusionRigorous clinical policies for the clinical management of incidental findings are needed because the sheer number of significant findings could prove overwhelming to health-care institutions, providers, and patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.